Biosimilar Red Tape Act (S. 1954)

Summary

Changes the rules so that once a drug is approved as a 'biosimilar,' it is automatically considered 'interchangeable' with the original, more expensive drug.

What problem does this solve?

Currently, biosimilar drugs must pass a second, costly approval step to be considered 'interchangeable' at the pharmacy, delaying access to cheaper options. This bill removes that extra step, allowing any approved biosimilar to be automatically substituted for its brand-name version.

What does this bill do?

Automatic interchangeability for biosimilars

Makes any biological drug approved as a 'biosimilar' automatically considered 'interchangeable' with the original brand-name drug. This removes the need for a separate, second approval step.

Establishes a transition period

Sets a 'transition date' 60 days after the bill becomes law. Biosimilars approved before this date become interchangeable on this date, while those approved after are interchangeable immediately.

Preserves existing market exclusivity

Ensures that any biosimilar drug that already earned an 'interchangeable' status under the old rules keeps its period of market exclusivity without competition.

Requires updated FDA guidance

Directs the government to update or cancel existing guidance documents for drug makers to match the new rules within 18 months of the bill becoming law.

Who does this affect?

Patients using biologic medicines
Pharmaceutical companies
Pharmacists and doctors

What is the real world impact?

•

Lowers prescription drug costs

Simplifies the approval process for biosimilar drugs, which are cheaper versions of complex medicines. This increases competition and can lead to lower prices for patients and insurance providers.

•

Reduces regulatory burdens

Eliminates what some see as an unnecessary and expensive step for drug makers to prove their biosimilar product is interchangeable. This saves time and money for companies developing these lower-cost alternatives.

When does this start?

The bill's changes take effect based on several deadlines after it becomes law.

Transition Date for Interchangeability

60 days after the bill becomes law, all previously approved biosimilars will be considered interchangeable.

Guidance Document Updates

The Secretary must update all related guidance documents for drug makers no later than 18 months after the bill becomes law.